NDT Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NDTP research report →
Price Chart
About the company
NDT Pharmaceuticals Inc., a biotechnology firm situated in Vienna, Virginia, is dedicated to formulating a range of treatments for serious neurological ailments, particularly those stemming from traumatic brain injuries.
- CEO
- James Hovis
- IPO
- 2008
- HQ
- Vienna, VA, US
Get TickerSpark's AI analysis on NDTP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $56.00M
- P/E
- -50.00
- PEG
- 0.21
- P/S
- 146.52
- P/B
- 1.29
- EV/EBITDA
- -65.56
- Div Yield
- 0.00%
- Gross Margin
- -145.05%
- Op Margin
- -365.55%
- Net Margin
- -366.41%
- ROE
- -5.17%
- ROIC
- -2.56%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-22,819
- Net Income
- $-22,819-36.7%
- EPS
- $0.00+100.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $2.10
- 52W Low
- $0.24
- 50D MA
- $0.44
- 200D MA
- $0.68
- Beta
- 0.00
- RSI (14)
- 27
- Avg Volume
- 2.12K
No earnings-call transcripts are available for NDTP yet.
- Free Float
- 35.2%
- Shares Outstanding
- 160.00M
- Float Shares
- 56.31M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 29, 07 | CARASQUERO FRANCISCO KENT | other | 96,000 |
| Mar 28, 07 | CARASQUERO FRANCISCO KENT | other | 0 |
| Mar 28, 07 | CARASQUERO FRANCISCO KENT | other | 0 |
| Jun 2, 06 | XINOS JOHN ANASTASIOS | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NDTP coverage
Recent articles, reports, and earnings notes.
No research on NDTP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NDTP report →Good Salt Life Expands Clean Republic Multipurpose Disinfectant Label with Hospital-Disinfectant Kill Claims, Opening the Door to Healthcare and Animal Care Markets
globenewswire.com · Aug 4
NDT Pharmaceuticals, Inc.'s Wholly Owned Subsidiary Good Salt Life, Inc. Reports Strong Online Retail Growth in First Half of 2026
globenewswire.com · Jul 15
NDT Pharmaceuticals Inc.'s Wholly Owned Subsidiary, Good Salt Life, Receives Official Green Seal® Certification for Clean Republic Multipurpose Disinfectant
globenewswire.com · Feb 5
NDT Pharmaceuticals' Wholly Owned Subsidiary Good Salt Life, Inc. Advances Toward Key Regulatory Milestones for Clean Republic® Multipurpose Disinfectant
globenewswire.com · Jan 8
NDT Pharmaceuticals, Inc.'s Wholly Owned Subsidiary, Good Salt Life, Inc., Launches Brands PurrGuard® and Dog Gone Odor®, EPA-registered Odor-killing Bacteria Chemistry for Companion Animals
globenewswire.com · Dec 19
Good Salt Life, Inc.'s Induction Charge Delivery Systems Deployed to Protect Show Horses from Widespread EHV-1 Outbreak
accessnewswire.com · Nov 26
NDT Pharmaceuticals' Subsidiary, Good Salt(TM) Life, Secures Major Government Contract, Deploying Advanced Biosafety Ecosystem in Tennessee State Prisons
accessnewswire.com · Nov 24
NDT Pharmaceuticals Showcases Strategic Value of Good Salt(TM) Life Acquisition with Expanded Relationship with Norwegian Cruise Line
accessnewswire.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.